Benlysta Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Benlysta is a biologic medication, also known as belimumab, primarily used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It works by targeting and inhibiting the BLyS protein, reducing B-cell survival, which helps decrease disease activity and prevent organ damage. Benlysta is administered either via intravenous infusion or subcutaneous injection.

The main modes of benlysta administration include intravenous (IV) and subcutaneous (SC) methods. Intravenous (IV) administration delivers medications, fluids, or nutrients directly into a vein, allowing rapid absorption into the bloodstream. Its clinical indications include systemic lupus erythematosus (SLE), lupus nephritis (LN), and other related conditions. Benlysta is used by various end users, including hospitals, clinics, home care settings, and specialty pharmacies, providing broad accessibility and flexibility in treatment.

Tariffs have impacted the benlysta market by increasing costs for monoclonal antibody manufacturing inputs, injectable delivery systems, and cold chain distribution. These pressures are seen across hospital and specialty pharmacy channels. Regions reliant on imported biologics face moderate pricing challenges. At the same time, tariffs are encouraging regional biologic manufacturing expansion. This supports long-term treatment continuity and supply resilience.

The benlysta market research report is one of a series of new reports from The Business Research Company that provides benlysta market statistics, including benlysta industry global market size, regional shares, competitors with a benlysta market share, detailed benlysta market segments, market trends and opportunities, and any further data you may need to thrive in the benlysta industry. This benlysta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The benlysta market size has grown rapidly in recent years. It will grow from $2404.67 million in 2025 to $2677.94 million in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to limited effective sle therapies, biologic drug innovation, early belimumab approvals, specialist rheumatology adoption, unmet autoimmune treatment needs.

The benlysta market size is expected to see rapid growth in the next few years. It will grow to $4073.18 million in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to rising lupus diagnosis rates, expanded indications such as lupus nephritis, improved biologic access, stronger reimbursement support, increased specialist awareness. Major trends in the forecast period include growing adoption of targeted autoimmune therapies, expansion of biologic treatments in lupus care, shift toward long term disease modifying agents, increased use of subcutaneous administration, rising focus on organ damage prevention.

The increasing incidence of autoimmune diseases is expected to drive the growth of the benlysta market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks healthy cells, tissues, or organs. The prevalence of these diseases is rising due to factors such as improved diagnosis, environmental triggers, lifestyle changes, genetic predisposition, and an aging population. Benlysta helps manage autoimmune conditions, particularly systemic lupus erythematosus (SLE), by targeting and inhibiting the B-lymphocyte stimulator (BLyS) protein, which is key to the overactive immune response. This reduces the survival of harmful B cells, preventing them from attacking healthy tissues, controlling disease activity, reducing flare-ups, and improving patient outcomes. For example, in March 2024, the National Health Council, a U.S.-based nonprofit organization, reported that autoimmune diseases affect around 50 million people in the United States, though this may underestimate true prevalence due to diagnostic challenges. Studies suggest annual increases in autoimmunity ranging from 3% to 12%, while the National Library of Medicine reported that global incidence of autoimmune diseases rises by 19.1% annually and prevalence by 12.5% each year. Therefore, the rising number of autoimmune cases is supporting growth in the benlysta market.

The growth in healthcare expenditure is expected to further propel the benlysta market. Healthcare expenditure refers to total spending on medical goods and services, including hospital care, pharmaceuticals, and healthcare administration, encompassing both public and private sector spending. Rising healthcare expenditure is driven by an aging population, increasing chronic disease prevalence, medical technology advancements, higher healthcare demands, and inflation. Greater healthcare spending supports the Benlysta market by facilitating investment in treatments for chronic autoimmune conditions like lupus, increasing demand for biologic therapies. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that between 2022 and 2023, healthcare spending in the UK increased by 5.6%, compared with 0.9% growth in 2022, reaching approximately $317.63 billion (£292 billion). Therefore, rising healthcare expenditure is driving the growth of the benlysta market.

Major companies in the benlysta market are focusing on innovations such as autoinjectors to improve treatment accessibility, adherence, and patient convenience. Autoinjectors are devices designed to deliver precise doses of medication quickly and easily, often allowing patients or caregivers to self-administer therapy at home, reducing the need for frequent clinic visits. For instance, in May 2024, GlaxoSmithKline plc, a UK-based pharmaceutical company, announced FDA approval of the Benlysta (belimumab) autoinjector for pediatric patients aged 5 years and older with SLE. This approval introduced the first at-home treatment option for children requiring belimumab, allowing subcutaneous administration without clinical visits every four weeks. The autoinjector enhances convenience and flexibility for caregivers, addressing the severe impact of lupus in children, including higher organ damage rates.

Major companies operating in the benlysta market are GlaxoSmithKline plc

North America was the largest region in the benlysta market in 2025. The regions covered in the benlysta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the benlysta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The benlysta market consists of sales of products such as immune system modulators, infusion equipment and biologic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Benlysta Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses benlysta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for benlysta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The benlysta market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Route Of Administration: Intravenous (IV); Subcutaneous (SC)
• 2) By Clinical Indication: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN); Other Related Conditions
• 3) By End Users: Hospitals; Clinics; Home Care Settings; Specialty Pharmacies
• Companies Mentioned: GlaxoSmithKline plc
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.